Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Up 25.9% in December

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 2,530,000 shares, a growth of 25.9% from the November 30th total of 2,010,000 shares. Based on an average trading volume of 328,900 shares, the days-to-cover ratio is presently 7.7 days. Approximately 8.2% of the shares of the stock are short sold.

Tyra Biosciences Trading Down 1.2 %

Shares of NASDAQ:TYRA traded down $0.17 during mid-day trading on Monday, reaching $13.90. The stock had a trading volume of 125,509 shares, compared to its average volume of 195,783. The firm has a 50 day simple moving average of $16.85 and a two-hundred day simple moving average of $19.39. Tyra Biosciences has a twelve month low of $11.24 and a twelve month high of $29.60. The firm has a market cap of $703.38 million, a PE ratio of -8.63 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, equities analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, CEO Todd Harris sold 10,035 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $24.31, for a total value of $243,950.85. Following the transaction, the chief executive officer now owns 1,467,338 shares of the company’s stock, valued at approximately $35,670,986.78. The trade was a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares of the company’s stock, valued at $7,635,587.19. This represents a 2.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 84,160 shares of company stock worth $1,827,047 over the last three months. 15.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after buying an additional 3,896 shares during the period. Franklin Resources Inc. acquired a new position in Tyra Biosciences in the 3rd quarter worth $278,000. Barclays PLC raised its stake in shares of Tyra Biosciences by 200.5% in the 3rd quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares during the period. State Street Corp raised its stake in shares of Tyra Biosciences by 4.4% in the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after purchasing an additional 16,248 shares during the period. Finally, Polar Asset Management Partners Inc. bought a new stake in shares of Tyra Biosciences in the third quarter valued at about $2,071,000. 84.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

TYRA has been the subject of several research analyst reports. HC Wainwright dropped their price objective on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $22.00 to $31.00 in a report on Friday, October 18th. Finally, Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.